Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…
Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
Noosa News18 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News24 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business23 hours agoAre BHP shares are buy after its results?
-
Business13 hours agoprofit up 7%, guidance strong